Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
- Written by PR Newswire
![]() |
SAINT-CLOUD, France, June 13, 2024 /PRNewswire/ -- Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical.
Leader in essential medicines for central nervous system, hospital care and internal...
Read more: Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China















